Clinical Trials

Alliance A011502

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer

Objective

This randomized phase III trial studies how well aspirin works in preventing cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

NCT# 02927249

Clinical Trial Categories

  • Breast Cancer
Contact
NH Oncology Hematology Clinical Research Dept. at 603-224-2556

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000